HK1151038A1 - 肽及含有 肽的疫苗 - Google Patents

肽及含有 肽的疫苗

Info

Publication number
HK1151038A1
HK1151038A1 HK11104995.4A HK11104995A HK1151038A1 HK 1151038 A1 HK1151038 A1 HK 1151038A1 HK 11104995 A HK11104995 A HK 11104995A HK 1151038 A1 HK1151038 A1 HK 1151038A1
Authority
HK
Hong Kong
Prior art keywords
kdr
peptides
vaccines
same
amino acid
Prior art date
Application number
HK11104995.4A
Other languages
English (en)
Inventor
Hideaki Tahara
Satoshi Wada
Takuya Tsunoda
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HK1151038A1 publication Critical patent/HK1151038A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464409—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
HK11104995.4A 2002-09-12 2009-05-15 肽及含有 肽的疫苗 HK1151038A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002267285 2002-09-12
JP2003062003 2003-03-07
JP2003167042 2003-06-11

Publications (1)

Publication Number Publication Date
HK1151038A1 true HK1151038A1 (zh) 2012-01-20

Family

ID=31998762

Family Applications (7)

Application Number Title Priority Date Filing Date
HK09104058.2A HK1124077A1 (en) 2002-09-12 2009-04-30 Kdr peptides and vaccines comprising the same
HK11104993.6A HK1151037A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗
HK11104977.6A HK1151032A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗
HK11104992.7A HK1151036A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗
HK09104475.7A HK1125659A1 (en) 2002-09-12 2009-05-15 Kdr peptides and vaccines comprising the same kdr
HK11104996.3A HK1151039A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗
HK11104995.4A HK1151038A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗

Family Applications Before (6)

Application Number Title Priority Date Filing Date
HK09104058.2A HK1124077A1 (en) 2002-09-12 2009-04-30 Kdr peptides and vaccines comprising the same
HK11104993.6A HK1151037A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗
HK11104977.6A HK1151032A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗
HK11104992.7A HK1151036A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗
HK09104475.7A HK1125659A1 (en) 2002-09-12 2009-05-15 Kdr peptides and vaccines comprising the same kdr
HK11104996.3A HK1151039A1 (zh) 2002-09-12 2009-05-15 肽及含有 肽的疫苗

Country Status (14)

Country Link
US (5) US7514084B2 (zh)
EP (11) EP2267023B1 (zh)
JP (3) JP3971769B2 (zh)
CN (5) CN101139393B (zh)
AT (2) ATE432291T1 (zh)
AU (1) AU2003264419A1 (zh)
CY (2) CY1109463T1 (zh)
DE (1) DE60327786D1 (zh)
DK (6) DK1548032T3 (zh)
ES (2) ES2375299T3 (zh)
HK (7) HK1124077A1 (zh)
PT (2) PT1548032E (zh)
SI (2) SI1548032T1 (zh)
WO (1) WO2004024766A1 (zh)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101139393B (zh) * 2002-09-12 2010-11-24 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
ES2459492T3 (es) * 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
PL2095822T3 (pl) * 2005-02-28 2014-03-31 Oncotherapy Science Inc Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
EP1915622A2 (en) 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP5539649B2 (ja) 2005-12-13 2014-07-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞移植のための足場
PL2059256T3 (pl) 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗
CN103784938A (zh) * 2007-02-16 2014-05-14 肿瘤疗法科学股份有限公司 脉络膜血管新生的疫苗疗法
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
EP2189471B1 (en) 2007-08-20 2017-10-04 Oncotherapy Science, Inc. Foxm1 peptide and medicinal agent comprising the same
BRPI0815578B8 (pt) * 2007-08-20 2021-05-25 Oncotherapy Science Inc peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
US20110111395A1 (en) 2008-02-14 2011-05-12 Jean-Marie Saint-Remy Cd4+cells with cytolytic properties
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
AU2009214042B2 (en) 2008-02-14 2014-02-13 Katholieke Universiteit Leuven Immunotherapy targeting intracellular pathogens
CA2715484C (en) 2008-02-14 2017-04-11 Life Sciences Research Partners Vzw Suppression of immune responses to viral vectors
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
NZ592461A (en) 2008-10-22 2012-12-21 Oncotherapy Science Inc Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI539160B (zh) * 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TW201032820A (en) * 2008-12-16 2010-09-16 Oncotherapy Science Inc ELOVL7 epitope peptides and vaccines containing the same
SG172374A1 (en) * 2008-12-24 2011-07-28 Oncotherapy Science Inc C1orf59 peptides and vaccines including the same
ES2728998T3 (es) 2009-01-08 2019-10-29 Int Inst Cancer Immunology Inc Nuevo antígeno de cáncer EEF2
SG174206A1 (en) * 2009-03-04 2011-10-28 Oncotherapy Science Inc Vangl1 peptides and vaccines including the same
PT2408913T (pt) 2009-03-18 2017-03-07 Oncotherapy Science Inc Péptidos neil3 e vacinas que incluem os mesmos
TW201100090A (en) * 2009-04-01 2011-01-01 Oncotherapy Science Inc C6orf167 peptides and vaccines containing the same
TWI507204B (zh) * 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
WO2011014871A1 (en) * 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
TW201200525A (en) * 2009-12-04 2012-01-01 Oncotherapy Science Inc MYBL2 peptides and vaccines containing the same
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
CN102115492B (zh) * 2010-01-05 2013-03-06 中国农业科学院北京畜牧兽医研究所 血管内皮生长因子受体部分多肽及其应用
CN102884190B (zh) * 2010-03-11 2016-03-23 肿瘤疗法科学股份有限公司 Hjurp肽及包含它们的疫苗
TW201134480A (en) * 2010-04-08 2011-10-16 Oncotherapy Science Inc CLUAP1 peptides and vaccines including the same
CN102947325B (zh) * 2010-04-09 2015-04-01 肿瘤疗法科学股份有限公司 Cdca5肽及包含它们的疫苗
WO2012032763A1 (en) * 2010-09-07 2012-03-15 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
LT2624873T (lt) 2010-10-06 2020-03-10 President And Fellows Of Harvard College Įšvirkščiami, poras sudarantys hidrogeliai, skirti medžiagų pagrindo ląstelių terapijai
US10023847B2 (en) 2010-11-25 2018-07-17 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
EA028216B1 (ru) * 2010-12-02 2017-10-31 Онкотерапи Сайенс, Инк. Пептиды tomm34 и содержащие их вакцины
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
EP2823824A4 (en) 2012-03-09 2015-09-16 Oncotherapy Science Inc PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE
AU2013249366B2 (en) 2012-04-16 2018-02-01 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
EP2848633B1 (en) 2012-05-11 2019-02-06 Microbial Chemistry Research Foundation Anti-cxadr antibody
JP6255593B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン
JP2016502499A (ja) * 2012-12-04 2016-01-28 オンコセラピー・サイエンス株式会社 Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
EP2955226B1 (en) 2013-02-08 2019-06-26 Medical & Biological Laboratories Co., Ltd. Antibodies to human nrg1 protein
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
JP2017042047A (ja) * 2013-12-06 2017-03-02 オンコセラピー・サイエンス株式会社 Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016129335A1 (ja) * 2015-02-09 2016-08-18 株式会社ライフアートビレッジ 免疫細胞療法のためのペプチドスクリーニング方法
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3939606A3 (en) 2015-09-25 2022-04-20 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
CN105200010B (zh) * 2015-10-15 2019-02-12 首都医科大学附属北京佑安医院 艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
KR20220132023A (ko) 2016-04-19 2022-09-29 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
US20200147194A1 (en) * 2017-05-19 2020-05-14 Keio University Peptide vaccine and peptide vaccine composition for cranial nerve disease
CN111363026B (zh) * 2020-03-31 2022-03-25 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种增强抗原多肽亲和力和稳定性的方法
KR20220022021A (ko) * 2020-08-14 2022-02-23 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
DE69434115T2 (de) * 1993-03-25 2005-10-27 Merck & Co., Inc. Inhibitor des wachstumsfaktors für gefässendothelzellen
JPH11510507A (ja) 1995-08-03 1999-09-14 リュークスウニベルジテート トゥ ライデン 細胞由来の抗原提示小胞
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US5942428A (en) * 1996-08-21 1999-08-24 Sugen, Inc. Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
JP3837748B2 (ja) * 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
DE69838334T2 (de) * 1997-06-18 2008-06-12 Merck & Co., Inc. (A New Jersey Corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1055684A4 (en) * 1997-12-05 2002-12-04 Kyogo Itoh TUMORANTIGENS IN THE FORM OF PEPTIDE DERIVATIVES
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
CA2328893A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
CN1318447C (zh) 1998-06-25 2007-05-30 伊东恭悟<Del/> 得自亲环蛋白b的肿瘤抗原肽
AU6600400A (en) * 1999-08-13 2001-03-13 Crucell Holland B.V. Methods and means for inhibiting angiogenesis
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
JP2002267285A (ja) 2001-03-12 2002-09-18 Denso Corp 冷房冷蔵装置
JP4068371B2 (ja) 2001-06-13 2008-03-26 株式会社トプコン 手術用顕微鏡
JP3640084B2 (ja) 2001-11-30 2005-04-20 日本電気株式会社 測位機能を搭載した携帯電話端末
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
CN101139393B (zh) * 2002-09-12 2010-11-24 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
EP2514420B1 (en) 2002-09-18 2014-08-13 Trustees Of The University Of Pennsylvania Use of rapamycin for the treatment or prevention of age-related macular degeneration
PL2095822T3 (pl) * 2005-02-28 2014-03-31 Oncotherapy Science Inc Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
CN103784938A (zh) 2007-02-16 2014-05-14 肿瘤疗法科学股份有限公司 脉络膜血管新生的疫苗疗法
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌

Also Published As

Publication number Publication date
JP4185143B2 (ja) 2008-11-26
US20130028923A1 (en) 2013-01-31
HK1151032A1 (zh) 2012-01-20
CN101139392B (zh) 2012-12-26
CY1113379T1 (el) 2016-06-22
DK2267022T3 (en) 2015-02-23
US8206719B2 (en) 2012-06-26
EP2014678A2 (en) 2009-01-14
EP2270042B1 (en) 2015-01-14
US8574585B2 (en) 2013-11-05
US20120328636A1 (en) 2012-12-27
DK2261249T3 (en) 2015-02-16
EP2261247A3 (en) 2011-02-16
EP1548032B9 (en) 2009-10-28
EP2267022A2 (en) 2010-12-29
WO2004024766A1 (ja) 2004-03-25
EP2267021A2 (en) 2010-12-29
CN101139392A (zh) 2008-03-12
EP2261248A3 (en) 2011-02-16
EP2267022B1 (en) 2015-02-11
EP2270042A3 (en) 2011-02-16
DK2014678T3 (da) 2012-02-06
HK1151039A1 (zh) 2012-01-20
JP2007277251A (ja) 2007-10-25
HK1151037A1 (zh) 2012-01-20
EP1548032B1 (en) 2009-05-27
SI2014678T1 (sl) 2012-03-30
CN1694901A (zh) 2005-11-09
PT2014678E (pt) 2012-01-05
US8574586B2 (en) 2013-11-05
EP2261249B1 (en) 2015-02-11
US20090252752A1 (en) 2009-10-08
JPWO2004024766A1 (ja) 2006-01-26
HK1151036A1 (zh) 2012-01-20
EP2267023A3 (en) 2011-02-16
PT1548032E (pt) 2009-08-13
EP2267023B1 (en) 2015-02-11
EP1548032A1 (en) 2005-06-29
EP2261249A2 (en) 2010-12-15
JP4185147B2 (ja) 2008-11-26
CN100352843C (zh) 2007-12-05
EP2270041A3 (en) 2011-02-16
EP2014678A3 (en) 2009-03-25
EP2267021B1 (en) 2015-02-18
HK1125659A1 (en) 2009-08-14
EP2014679B1 (en) 2010-05-05
ATE432291T1 (de) 2009-06-15
ATE531729T1 (de) 2011-11-15
EP2270042A2 (en) 2011-01-05
EP2267022A3 (en) 2011-02-16
CN103951745A (zh) 2014-07-30
CY1109463T1 (el) 2014-08-13
CN103073620B (zh) 2014-12-10
EP1548032A4 (en) 2006-03-01
ES2375299T3 (es) 2012-02-28
EP2267021A3 (en) 2011-02-16
US7514084B2 (en) 2009-04-07
DK1548032T3 (da) 2009-08-17
EP2261249A3 (en) 2011-02-16
AU2003264419A1 (en) 2004-04-30
CN103073620A (zh) 2013-05-01
EP2014678B1 (en) 2011-11-02
CN101139393A (zh) 2008-03-12
US20060216301A1 (en) 2006-09-28
DK2267023T3 (en) 2015-02-23
EP2270041A2 (en) 2011-01-05
SI1548032T1 (sl) 2009-10-31
EP2014679A1 (en) 2009-01-14
DK2267021T3 (en) 2015-03-30
US7695720B2 (en) 2010-04-13
EP2261248A2 (en) 2010-12-15
JP2007191485A (ja) 2007-08-02
DE60327786D1 (de) 2009-07-09
ES2327040T3 (es) 2009-10-23
EP2261247A2 (en) 2010-12-15
HK1124077A1 (en) 2009-07-03
CN101139393B (zh) 2010-11-24
EP2267023A2 (en) 2010-12-29
JP3971769B2 (ja) 2007-09-05
EP2270041B1 (en) 2015-02-25
EP2261248B1 (en) 2015-02-18
US20100215676A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
HK1125659A1 (en) Kdr peptides and vaccines comprising the same kdr
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
HK1134507A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
GB0202556D0 (en) Novel Protein
DK2289533T3 (da) Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
EP1548107A4 (en) CHROMOPROTEIN AND FLUOROPROTEINS
ATE196926T1 (de) Gen grb3-3, variante und ihre verwendungen
ATE501256T1 (de) Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
MX2010005816A (es) Epítopos de péptido de stat3.
EP2370454A4 (en) PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM
WO2002034882A3 (en) Genes regulating programmed cell death
CY1114627T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180915